MedPath

Bioequivalance study of Metformin 1000 mg Tablets

Not Applicable
Conditions
Bioequivalance Metformin 1000 mg.
Registration Number
IRCT20200513047423N8
Lead Sponsor
Sana Med
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
24
Inclusion Criteria

Healthy liver
Healthy kidney
Volunteers should not be too fat or too thin and their weight index should be in the appropriate range

Exclusion Criteria

Out of age ranges
smoking
pregnancy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Plasma concentration changing after administration of Metformin 1000 mg tablet.Plasma concentration of Metformin at Tmax reaches about 1800 ng/mL and its measurement range is from 25ng / mL to 3000ng / mL. Timepoint: Initial blood sampling is performed before drug administration to obtain blank plasma chromatogram of each volunteers. Hence the Tmax of Metformin is between 1.5 and 3 hours, so it is needed to have 5 blood sampling before Tmax. This period of time is called absorption phase. In the elimination phase (after Tmax) blood sampling carry out each hours. Sampling is done in 10 and 24 hours. Method of measurement: In this study, the variable is plasma concentration of Metformin. High performance liquid chromatography is used to determine the concentration of metformin in plasma.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath